Akero Therapeutics: Cirrhosis Reversal Data Derisks The Stock

Group 1 - Akero Therapeutics (NASDAQ: AKRO) experienced a significant stock increase, more than doubling in January due to positive Phase 2b study results for efruxifermin (EFX) targeting metabolic dysfunction-associated steatohepatitis (MASH) [1] - The study revealed that 39% of patients treated with EFX showed a reversal of their condition [1] Group 2 - Total Pharma Tracker offers tools for DIY investors, including a software that provides extensive curated research material for any ticker [2] - For investors seeking hands-on support, in-house experts analyze tools to identify the best investable stocks, along with buy/sell strategies and alerts [2]